TRxADE HEALTH, INC. Appoints Leading Pharmaceutical Industry Expert Mr. Jeff Newell to its Advisory Board
TRxADE Health (NASDAQ:MEDS) announced the appointment of Jeff Newell to its advisory board on August 16, 2022. Newell, a seasoned executive with over 40 years of healthcare experience, is expected to enhance TRxADE's trade relationships and stockholder value. His background includes various leadership roles in the pharmaceutical sector, which the company believes will provide valuable insights moving forward. TRxADE operates a drug procurement marketplace serving over 13,800 members and aims to digitalize the retail pharmacy experience in the U.S.
- Appointment of Jeff Newell expected to enhance trade relationships and stockholder value.
- Newell's extensive experience in the healthcare industry brings valuable insights.
- TRxADE has a strong market position in the pharmaceutical trading space.
- No specific financial metrics or performance indicators were mentioned regarding the impact of the appointment.
TAMPA, FL / ACCESSWIRE / August 16, 2022 / TRxADE HEALTH, INC. (NASDAQ:MEDS) ("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., announced today the appointment of Jeff Newell to the Company's advisory board. Mr. Newell is expected to serve as a strategic resource to TRxADE as it continues to develop trade relationships in the industry.
"We are thrilled to add industry experts like Mr. Newell to the Advisory Board and look forward to working with him to build stockholder value," said Suren Ajjarapu, Chairman of the Board, who continued, "We are committed to fostering long-term growth and we believe we have the personnel resources and leadership in place to achieve this goal. We are excited about this new relationship and believe that the background and experience that Mr. Newell brings to TRxADE is going to be invaluable and that we will benefit from having access to Mr. Newell's expertise."
"TRxADE Health is a leader in Pharmaceutical Trading platforms with innovative, market-leading technologies, and we believe that the Company is well-positioned to take advantage of multiple opportunities," said Donald Fell, member of the Company's Board of Directors, who continued, "As an Advisory Board Member, Mr. Newell will work with the directors and the management team to enhance the value of the Company for all stockholders. His record shows that his involvement on boards has often created meaningful value for all stockholders and we expect this to continue with TRxADE."
Mr. Fell added, "Given his experience and broad knowledge in the Pharmaceutical space, I believe that Mr. Newell will be an extremely valuable resource to the Company going forward."
About Mr. Jeff Newell:
Mr. Newell is an accomplished Chief Executive Officer who has over forty years of experience in the healthcare industry with a proven track record of growing profitable organizations through strategic initiatives and the development of high-performance teams. Mr. Newell is skilled in Operations, Patient Engagement, Compliance, Regulatory Affairs, Quality Measurement, Supply Chain, and Product Sourcing. Mr. Newell is a strong entrepreneurship professional with a Bachelor of Science (B.S.) focused in Pharmacy from Albany College of Pharmacy & Health Sciences. Mr. Newell has held various executive level positions including President & CEO for Newell Group, CEO of Pharmacy Quality Solutions, Vice President Pharmacy Administration & Head of Compliance of Sears Holding/Kmart Pharmacy, and Senior Vice President of Operations and Chief Compliance Officer of Millennium Pharmacy Systems. As part of his long career in healthcare and pharmacy, Mr. Newell was Director of Pharmacy Programs /Manager of Regulatory Affairs at CVS. Throughout his career, Mr. Newell has served on many National, State and Local Boards, within the Healthcare Industry.
Mr. Newell is retired and stays active within the industry through his consulting company. He consults with a select number of companies and individuals and leverages his expertise and vast network to drive improved performance.
About TRxADE HEALTH, Inc.
TRxADE HEALTH, Inc. (NASDAQ:MEDS) is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S. The Company operates the TRxADE drug procurement marketplace serving a total of 13,815+ members nationwide, fostering price transparency and under the Bonum Health brand, offering patient centric telehealth services and tele vet services. For more information on TRxADE Health, please visit the Company's IR website at investors.trxadehealth.com.
Forward-Looking Statements
This press release may contain forward-looking statements, including information about management's view of TRxADE's future expectations, plans and prospects, within the meaning of the federal securities laws, including the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "will," "would" and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of TRxADE, its divisions and concepts to be materially different than those expressed or implied in such statements. These risks include risks relating to agreements with third parties, including Coborn's and Galt Pharmaceuticals; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; the planned benefits, expected users of, and projected revenues of our venture with Exchange Health; amounts we owe and may owe to Exchange Health in connection with the arrangement with Exchange Health; security interests under certain of our credit arrangements; the fact that we are exploring strategic alternatives for our Bonum Health, Inc. subsidiary; our operations not being profitable; the commercial viability of new business lines, applications, products and technologies, and the costs of such items; the Company's stock repurchase program; the adoption of the Company's product offerings; claims relating to alleged violations of intellectual property rights of others; our ability to monetize our technological solutions; technical problems with our websites, apps and products; risks relating to implementing our acquisition strategies; challenges to the pharmaceutical supply chain posted by the COVID-19 pandemic and related matters; our ability to manage our growth; negative effects on our operations associated with the opioid pain medication health crisis; regulatory and licensing requirement risks; risks related to changes in the U.S. healthcare environment; the status of our information systems, facilities and distribution networks; risks associated with the operations of our more established competitors; regulatory changes; new competitors which may have more resources than we do; increases in direct to consumer sales of drugs; healthcare fraud; COVID-19, governmental responses thereto, economic downturns and increased inflation and possible recessions caused thereby; changes in laws or regulations relating to our operations; privacy laws; system errors; dependence on current management; our growth strategy; dilution which may be caused by future offerings; increased inflation, increases in interest rates and supply chain issues; and others that are included from time to time in filings made by TRxADE with the Securities and Exchange Commission, including, but not limited to, in the "Risk Factors" sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which it has filed, and files from time to time, with the U.S. Securities and Exchange Commission (SEC), and more particularly in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, and our Annual Report on Form 10-K for the year ended December 31, 2021. These reports are available at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on TRxADE's future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. TRxADE cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Investor Relations:
IR@trxade.com
Investors.trxadegroup.com
SOURCE: TRxADE HEALTH, Inc.
View source version on accesswire.com:
https://www.accesswire.com/712184/TRxADE-HEALTH-INC-Appoints-Leading-Pharmaceutical-Industry-Expert-Mr-Jeff-Newell-to-its-Advisory-Board
FAQ
What is the significance of Jeff Newell's appointment to TRxADE (MEDS)?
What experience does Jeff Newell bring to TRxADE (MEDS)?
How many members does TRxADE's drug procurement marketplace serve?
What is TRxADE Health's focus in the market?
